Last checked at 
LONDON (Alliance News) - ReNeuron Group PLC said Wednesday it expects to enroll the first patient in its stroke disability study "shortly".
The company said that the first clinical site has been initiated in the US Phase IIb study, with its CTX cell therapy as a candidate for stroke disability.
"The primary end-point of the study is the proportion of patients in the treated and placebo arms showing a clinically important improvement on the modified Rankin Scale (mRS) at six months post-treatment compared with baseline," the company said.
The mRS is a global measure of disability which depends on a person's dependence on others.
The company expects data from the study in early 2020, "slightly later than planned".
ReNeuron shares were trading up 1.9% at 84.60 pence each on Wednesday.
